Internationally recognized for novel approaches to treating leukemia, lymphoma, and myeloma
The Duke Adult Blood and Marrow Transplant (ABMT) Program is internationally recognized for its novel approaches to treating leukemia, lymphoma, and myeloma through bone marrow, cord blood, and stem cell transplantation.
We also treat novel indications such as autoimmune disease and hemoglobinopathies.
A leading center of clinical care, medical education, and biomedical research, Duke is consistently ranked among the nation’s premier health care institutions.
The Duke Blood and Marrow Transplant Program is closely associated with the Duke Cancer Institute, consistently rated among the nation’s top cancer programs by U.S.News & World Report.
Patients benefit directly from Duke’s leadership in cancer research thanks to a “bench-to-bedside” approach that focuses on making promising new therapies quickly available to those who need them most.
Duke has earned national and global recognition for its leadership in bone marrow and stem cell transplantation. Duke doctors were among the first to successfully use these techniques in the treatment of many types of pediatric and adult cancers.
The ABMT’s interdisciplinary team, led by director Nelson Chao, MD, is committed to providing the best care to each individual patient.